A Single Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusion and Intravenous Bolus Administration of MK-2060 in Healthy Participants
Latest Information Update: 28 Oct 2024
Price :
$35 *
At a glance
- Drugs MK 2060 (Primary)
- Indications Venous thrombosis
- Focus Adverse reactions
- Acronyms MK-2060-016
- Sponsors Merck Sharp & Dohme
- 23 Oct 2024 Planned End Date changed from 31 Mar 2025 to 3 Jun 2025.
- 23 Oct 2024 Planned primary completion date changed from 31 Mar 2025 to 3 Jun 2025.
- 21 Oct 2024 Status changed from not yet recruiting to recruiting.